PET or MRI to improve response evaluation in clinical trials?

Deroose, Christophe M;Gheysens, Olivier;Perez-Lopez, Raquel
(2019) The Lancet Oncology — Vol. 20, n° 8, p. 1060-1062 (2019)

Files

2019_Deroose_Lancet_Oncol.pdf
  • Restricted Access
  • Adobe PDF
  • 509.46 KB
Request a copy

Details

Authors
Abstract
PET is an imaging technique providing three-dimensional depiction and (semi-)quantification of the regional distribution of radiopharmaceuticals, with very high sensitivity (picomolar range) and spatial resolution up to 4 mm. PET radiopharmaceuticals are designed to target molecular or biological processes relevant to cancer. Contemporary PET scanners are coupled with CT or MRI scanners for hybrid imaging to enhance the precise anatomical location of tracer accumulation. Tracer uptake can be assessed visually or semi-quantitatively. [...]
Affiliations
  • UZ LeuvenDepartment of Nuclear Medicine

Citations

  • APA
  • Chicago
  • FWB

Deroose, C. M., Gheysens, O., & Perez-Lopez, R. (2019). PET or MRI to improve response evaluation in clinical trials? The Lancet Oncology, 20(8), 1060-1062. https://doi.org/10.1016/S1470-2045(19)30465-6 (Original work published 2019)